Prostate Volume Changes Following Prostate Brachytherapy With Iodine-125 Seeds
NCT ID: NCT00348465
Last Updated: 2020-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
29 participants
OBSERVATIONAL
2006-05-31
2008-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
I125 Brachytherapy After TURP
NCT02370992
Implant Radiation Therapy Using Radioactive Iodine in Treating Patients With Localized Prostate Cancer
NCT00534196
Quality of Life After Permanent Interstitial Iodine Seed Prostate Brachytherapy
NCT02652000
Ability of a New Design of Iodine 125 Seed to Maintain Intended Position When Implanted in the Prostate
NCT01174017
Observational Study on Extreme Hypofractionation for Localized Prostate Cancer
NCT05344235
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Brachytherapy with Iodine-125 seeds
Brachytherapy of the prostate, and measurements of the prostate volume using CT scan and TURS
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* T1-3 disease
* PSA \<20 ng/ml
* Patient must sign a study-specific informed consent prior to enrollment.
Exclusion Criteria
18 Years
80 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
New York Presbyterian Brooklyn Methodist Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hani Ashamalla, MD
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hani Ashamalla, MD, FCCP
Role: STUDY_CHAIR
New York Presbyterian Brooklyn Methodist Hospital
Ewa Bieniek, MD
Role: PRINCIPAL_INVESTIGATOR
NY Methodist Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NYM-353
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.